Document 2452
 DOCN  M94A2452
 TI    Survival among injecting drug users with AIDS, United States, 1988-1990.
 DT    9412
 AU    Neal JJ; Fleming PL; Green TA; Chu SY; Burgess DA; Centers for Disease
       Control and Prevention, Atlanta, GA 30333.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):300 (abstract no. PC0126). Unique
       Identifier : AIDSLINE ICA10/94370123
 AB    OBJECTIVE: Most estimates of survival time after AIDS diagnosis have
       been based on studies of white men who have sex with men (MSM). We
       examined survival time after AIDS diagnosis among heterosexual injecting
       drug users (IDUs). METHODS: Reports of persons > or = 15 years of age
       with AIDS diagnosed from 1988 through 1990 and reported to CDC through
       June 1993 were selected from the 14 states and 3 cities that cross-match
       AIDS reports with the National Death Index. We used the product-limit
       method to calculate median survival time in months after AIDS diagnosis
       and survival time by year of diagnosis for MSM and IDUs. For IDUs, we
       also calculated survival time by sex, race/ethnicity, and geographic
       region of residence. Observations were censored in June 1992 to minimize
       bias caused by reporting delays. Differences in survival time were
       tested for significance at the p < .01 level. RESULTS: The median
       survival time was shorter for IDUs (14 months, n = 14,760) than for MSM
       (19 months, n = 34.425). Survival time increased by diagnosis year from
       1988 through 1992 among both IDUs (13 months to 16 months) and MSM (18.5
       months to 20 months). Among IDUs, survival time was shorter for older
       persons (11 months for persons aged 45-64) than for younger persons (19
       months for persons aged 15-24), for blacks and Hispanics (both 13
       months) than for whites (19 months), and for persons living in the
       Northeast (13 months) than in other regions (19 months). No significant
       differences in survival time by sex were found. DISCUSSION AND
       CONCLUSIONS: Differences in survival time by risk, diagnosis year, age,
       race, and region may be attributable to the effects of injected drugs or
       to differences in access to and use of HIV-related and other health-care
       services.
 DE    Acquired Immunodeficiency Syndrome/*MORTALITY/TRANSMISSION  Adolescence
       Adult  Female  Human  Male  Middle Age  Substance Abuse,
       Intravenous/*COMPLICATIONS  United States/EPIDEMIOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).